Old Silver VC is an evergreen family-associated fund that makes early stage investments in Biotech, Digital Health, AI, and Material Sciences. We believe that the world’s greatest problems can be solved with innovative science and technology solutions. We seek and support early-stage founders with a vision that can scale from science fiction to new reality.
Michael is the Founding Partner at Old Silver VC, the Head of Search and Evaluation at Pear Therapeutics and a World Economic Forum Global Shaper.
Vice President of Business Development at a Cambridge-based cell state start up in stealth mode.
Andrew Emmons, MBA
Focuses on early-stage investments in the technology, SaaS, and healthcare industries.
Well versed in corporate development and strategic & operational excellence focusing on biotechnology and healthcare.
Passionate about companies building high impact solutions at the intersection of health and technology. Currently supporting Growth at Oscar Health.
Cristiano Peron, MD
Physician-scientist currently completing his PhD at the University of Oxford. He focuses on translational research in Oncology.
M.D. candidate at Harvard-MIT with a focus on early-stage investments in the life sciences and health care space.
Senior software engineer at Microsoft whose expertise spans multiple verticals of the software engineering domains and a number of programming languages including C, C++, C# and Python.
David Mou, MBA, MD
Chief Medical Officer at Cerebral & Co-founder / former CMO of Valera Health, a venture-backed digital healthcare company.
Emilia Javorsky, MD, MPH
Physician-Scientist and former Harvard Medical School researcher focused on the development and translation of medical technologies.
Everett Crosland, MS, JD
Life sciences executive, with a proven track record commercializing and scaling complex drugs, drug-device combos, and digital therapeutics.
Co-founder of ThoughtMetric Inc- a next-generation analytics platform designed to help Mid-Market and SMB eCommerce stores better understand their customers.
Jordan Haviland, MBA
CEO of Brattle Point, LLC, where he focuses on acquiring growing technology and service businesses in scientific and industrial markets.
Livio Valenti, MPP
Sustainability entrepreneur and co-founder of Vaxess Technologies, a biotechnology company reimagining vaccine delivery.
Liz Kwo, MD, MBS, MPH
Deputy Chief Clinical Officer at Anthem & Co-Founder / former CEO of InfiniteMD.
Louis Kang, PhD
Managing Director at AccelR8, Co-Founder at MitoLab, Venture Partner at Korea Technology Bank (KTB) VC
Fund advisor specializing in life sciences and biotechnology investments. He brings over 7 years of industry experience as both a bioengineer and business development professional.
Founding Partner at First Star Ventures, an early-stage venture fund focuses on cutting edge data technologies.
Venture Partner at Arkitekt Ventures & Business Development at Capsule
Rebecca Maynard, LLM, JD
Compliance & Privacy Specialist at Boston Children's Hospital
Head of CX at NLP startup Forethought.ai, winner of TechCrunch Disrupt and funded by NEA, Village Global, K9 Ventures, etc.
Ryan Coles, MS, PHD
Assistant Professor of Entrepreneurial Management at UConn's School of Business, and the Chief Science Officer at Human Wealth.
Sean Cheng, MP, PHD
Early stage investor in health tech companies and is currently excited about digital therapeutics, remote patient care, novel devices, and disruptive enablers.
Sophie Bai, MBA
Founder and CEO of a biotech company using novel transdermal drug delivery technologies to get large molecules into the skin.
Zack Gow, ME, MS
Data scientist, machine learning engineer, and entrepreneur.
Freddie Martignetti, MBA
Investor at Highland Capital Partners, a global leader in early stage consumer and enterprise technology investments.
Robert Langer, Sc. D
Dr. Langer is one of 10 Institute professors at MIT (MITs highest honor). He is an expert in the fields of tissue engineering and drug delivery and has founded over 40 startup companies. He is the most cited engineer in history.
Prior Investments or Early Shareholder Positions